Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.

doi:10.1016/j.leukres.2022.106808

Back to search

Article

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.

Leukemia research - 1 Mar 2022

Nuhoğlu Kantarcı Eda, Eşkazan Ahmet Emre

Abstract excerpt

Acute myeloid leukemia (AML) is defined as a highly progressive heterogeneous hematologic malignancy characterized by loss of differentiation with uncontrolled proliferation of progenitor cells. 5-year overall survival rates are as low as 5-10% in adults above 60 years. Until recently, available...

Topics

Adult
Aniline Compounds
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Pyrazines
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.